Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Current guidelines recommend caution in prescribing concomitant use of direct-acting oral anticoagulants (DOACs) and antiepileptic drugs due to drug-drug interactions leading to potential risk of DOACs subtherapeutic concentration and treatment failure. Herein we report a significant interaction between carbamazepine (CZP) and apixaban, causing subtherapeutic concentration of the drug in a patient with atrial fibrillation who had a transient ischemic attack (TIA) episode. Another anti-Xa DOAC, edoxaban, administered to the patient after TIA occurrence did not show significant interaction with CZP. In addition to confirm that cautions should be used when antiepileptic and DOACs are concomitantly prescribed, the present case also demonstrates that, in the management of certain subsets of patients who need anticoagulant treatment, measurement of DOAC plasma concentration can help guide a personalized management and avoid adverse clinical outcomes.
Original languageEnglish
Pages (from-to)528-531
Number of pages4
JournalJOURNAL OF THROMBOSIS AND THROMBOLYSIS
Volume2019
DOIs
Publication statusPublished - 2019

Keywords

  • Anti-Xa activity
  • Carbamazepin
  • DOAC interaction
  • Direct oral anticoagulant
  • Personalized oral anticoagulant therapy

Fingerprint

Dive into the research topics of 'Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy'. Together they form a unique fingerprint.

Cite this